CIAM
LRMR icon

Caitong International Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Caitong International Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Buy
31,347
+30,159
+2,539% +$121K 0.03% 477
2025
Q4 		$4.53K Buy
+1,188
New +$4.62K ﹤0.01% 1244

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Caitong International Asset Management's LRMR Position: Q1 2026 in Review

Caitong International Asset Management increased its Larimar Therapeutics (LRMR) stake by 2,539% in Q1 2026, buying an estimated $121K and bringing the position to 31,347 shares worth $141K. The position accounts for 0.03% of the portfolio, ranked #477.

Caitong International Asset Management first reported a position in LRMR in Q4 2025 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Caitong International Asset Management held 31,347 shares of Larimar Therapeutics worth $141K as of Q1 2026.
  • Caitong International Asset Management bought 30,159 Larimar Therapeutics shares in Q1 2026, an estimated $121K.
  • Larimar Therapeutics made up 0.03% of Caitong International Asset Management's portfolio in Q1 2026, its #477 holding.
  • Caitong International Asset Management first reported a position in Larimar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.